Immuno-Oncology for Solid Tumors: Overcoming Barriers in the Tumor Microenvironment from thescientistllc on Vimeo.
The solid tumor microenvironment is immunosuppressive and poses a significant obstacle to achieving clinical success with various immunotherapies. Most notably, immune checkpoint pathways, including PD-1, PD-L1, and CTLA-4, allow tumors to evade the body’s usual immune reaction, leading to disease progression. Checkpoint blockade via monoclonal antibodies results in augmented T-cell activation and proliferation to enhance the anti-tumor immune response and has revolutionized the field, but not all patients are candidates and severe adverse effects persist. Therefore, the development of other approaches, such as antibody-drug conjugates, vaccines, and adoptive cell-based therapies, has surged. Recent advances in immunotherapy have certainly produced enhanced treatment options for solid tumors, but obstacles to their mainstream use remain. To explore novel strategies in immuno-oncology for solid tumors, The Scientist is bringing together a panel of experts to share their research and insights ...
